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A B S T R A C T
More attention is increasingly being paid to quality of life of people suffering from
schizophrenia. The results of numerous clinical trials indicate that novel antipsychotic
drugs are as efficient (if not more so) than the conventional drugs. Novel drugs also
cause fewer side effects and allow for better quality of life. In order to confirm these the-
sis we have studied the quality of life of 80 female outpatients in good social remission
that have been under psychiatric evaluation for at least six months and were on antipsy-
chotic drugs. Of those 80 outpatients, half were on the conventional medication, while
the other half were on the novel antipsychotic drugs. Their life quality was evaluated
with the questionnaire »Heinrichs-Hanlon-Carpenter – Quality of life questionnaire«,
which is one of the most frequently used QL scales. The results demonstrate that the
only difference between the two groups lies in the field of social activity. While leaving
the question of different influence of novel and conventional drugs open, the authors are
trying to find the possible reasons for such results.
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Introduction
In recent years, the view has prevailed
that medicine should serve not only to
heal the illness, but also to improve the
quality of life of those receiving the treat-
ment. The issue of quality of life is partic-
ularly important if the patients in ques-
tion are suffering from chronic illnesses1.
Among such patients, psychiatric pa-
tients, particularly the ones suffering
from schizophrenia, stand out because
their quality of life has always been sub-
stantially lower than the quality of life of
other categories of patients2–4.
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This is due to the fact that schizophre-
nia is a disease, which, among others, en-
ables patients to delude their subjective
assessment from the objective reality.
The whole array of so-called positive and
negative symptoms makes it impossible
for the patients to adequately participate
in a range of social activities5. With time,
the disease can totally eradicate the per-
sonality. Under the influence of psycho-
pathology, as well as in the state of chro-
nification, the quality of life of these pa-
tients is relatively low. Owing to research
and development of various antipsychotic
drugs in the last fifty years, the treat-
ment of schizophrenic patients has im-
proved so much that many of them can
live almost normal lives, if they take
their medications regularly6. Neurolep-
tics, or conventional antipsychotics, i.e.
antipsychotics of the first generation
have made possible the process of de-
hospitalization of mental patients, and
antipsychotics of the second generation,
i.e. novel antipsychotics, made it possible
to reintegrate the schizophrenic patients
into social environment7,8. Due to new
generation of antipsychotics the focus of
the treatment has been shifted to the out-
come of the illness and on the quality of
life9,10. The outcome of the illness and the
quality of life of schizophrenic patients,
as well as their rehabilitation, while us-
ing novel antipsychotic drugs, are seve-
rely influenced by various sociotherapeu-
tic and psychotherapeutic actions, which
cannot be neglected11.
Owing to the fact that many empha-
size the advantages of the new genera-
tion of antipsychotics compared to the
conventional antipsychotics (which are
more difficult to obtain to our patients*),
we wanted to verify on our own patients
whether there is a difference between the
quality of life of patients taking novel
antipsychotics and the quality of life of
patients taking conventional antipsycho-
tics. Our hypothesis was that patients
taking novel medications have a better
quality of life.
Materials and Methods
Two groups of 40 schizophrenic female
outpatients were involved in the re-
search. Each group has been in satisfac-
tory social remission for at least six
months, under regular psychiatric evalu-
ation, and under regular antipsychotic
medications therapy. First group consis-
ted of patients that were treated with
conventional antipsychotics, and the sec-
ond group was treated with novel anti-
psychotics. The age of the studied pa-
tients was between 23 and 67 (Figure 1),
and the duration of the disease was be-
tween 1 and 34 years (Figure 2). Patients
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* Atypical antipsychotics olanzapin and risperidon are available to our patients at the expense of the health in-
surance only if the »disease is refracteous to conventional antipsychotics or if the conventional antipsychotics
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Fig. 2. Duration of disease.
involved in the study have been selected
by random selection. Each patient that
came to control examination in the period
between 1st of July and 1st of October
2002, and fulfilled the given criteria was
included in the study. Since our patients
are still treated with conventional drugs
2–3 times more often then with novel
antipsychotics, each second or third pa-
tient that was treated with conventional
antipsychotics was included in the stu-
dy13. Only female patients were involved
in the study because psychiatrists that
carried out the research work on hospital
wards that treat only women, and con-
tinue to care for the same patients after-
wards as outpatients.
The research was conducted in the fol-
lowing manner: the psychiatrist would
conduct a structured interview, followed
by the examination, and then filled out
the questionnaire for the quality of life
according to »Heinrichs-Hanlon-Carpen-
ter – Quality of life questionnaire«15. The
comparison of the studied groups was
made by analysis of significance with
t-test.
Results
The results of the study are shown in
Figures 3 and 4 and Table 1. As can be
seen from the Figure 3, the studied pa-
tients have mostly taken flufenazin
(67.5% of cases), when taking conven-
tional antipsychotics, and of the novel
antipsychotics (Figure 4), olanzapin was
the mostly used.
The results of analysis according to
»Heinrichs-Hanlon-Carpenter – Quality
of life questionnaire« are given in Table 1.
Statistically significant difference was
found only in the category of Social activ-
ity, while other categories did not exhibit
statistically significant differences. So-
cial activity was better in the group using
the novel antipsychotics.
Discussion
Numerous studies show that the im-
portant benefits of novel antipsychotics is
their influence on improving the quality
of life of schizophrenic patients. Because
of this, and in line with tendencies of in-
sistence on the quality of life of (schizo-
phrenic) patients, advantage is given to
the group of novel antipsychotics over
conventional ones16. Wishing to test the
hypothesis that novel, atypical antipsy-
chotics are better then the conventional,
we have tested and compared the quality
of life of two groups of patents that were
selected in such a manner that this hy-
pothesis can be verified.
As we can see from Table 1 containing
obtained results, our hypothesis, based
on the suggestions of numerous studies,
was not proven.
Only one parameter that points to
quality of life according to »Heinrichs-
Hanlon-Carpenter – Quality of life ques-
tionnaire«, was improved by using novel
instead of conventional antipsychotics
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Fig. 3. Ratio of clasic antipsychotics in therapy.










Fig. 4. Ratio of new generation antipsychotics
in therapy.
and that's social activity (t = –2.09; p =
0.03). Although there is no statistically
significant difference in parameters of re-
treat from surroundings, life plans and
goals, motivation, curiousness and an-
hedony, it seems that tendency of novel
antipsychotics to improve these elements
of quality living can be perceived. Other
studied parameters of quality of life (rela-
tionship with household members, rela-
tionship with other people, active ac-
quaintances, social surrounding taking
care of the patient, social initiative,
psychosexual relations, working activi-
ties, achievements, inadequate employ-
ment, degree of satisfaction with own
functioning, usefulness of time, capacity
of engagement and emotional interaction
with interviewer with questionnaire) do
not differ in two studied groups of pa-
tients.
How does one comment these results?
It is obvious that the answer can’t and
shouldn’t be one-sided unambiguous. It
would be too early and rather pretentious
to discard the thesis that novel antipsy-
chotics improve the quality of life of schi-
zophrenic patients when compared with
conventional antipsychotics. But, consid-
ering results, this thesis can not be ne-
glected – results of this research show
that there is no significant difference in
the quality of life of schizophrenic pa-
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TABLE 1
RESULTS OF ANALYSIS USING »HEINRICHS-HANLON-CARPENTER – QUALITY OF LIFE
QUESTIONNAIRE« BETWEEN FEMALE PATIENTS USING CONVENTIONAL ANTIPSYCHOTICS
AND FEMALE PATINETS USING NOVEL ANTIPSYCHOTICS
No. Items t p
1. Rate intimate relationships with household members –.841 0.4
2. Rate intimate relationships –1.62 0.1
3. Rate active acquaintances –1.35 0.1
4. Rate level of social activity –2.09 0.03
5. Rate involved social network –1.61 0.1
6. Rate social initiatives –1.56 0.1
7. Rate social withdrawal –1.73 0.08
8. Rate sociosexual relations 0.31 0.7
9. Rate of extent of occupational role functioning 0.02 0.9
10. Rate level of accomplishment –1.36 0.1
11. Rate degree of underemployment –0.55 0.5
12. Rate satisfacition with occupational role functioning 0.21 0.8
13. Rate sense of purpose –1.68 0.09
14. Rate degree of motivation –1.73 0.08
15. Rate curiosity –1.79 0.07
16. Rate anhedonia –1.74 0.08
17. Rate time utilization –1.21 0.2
18. Rate capacity for empathy –1.38 0.1
19. Rate capacity for engagement and emotional interaction
with interviewer
–0.96 0.3
tients whether they use novel or conven-
tional antipsychotics.
Let’s consider, however, other alterna-
tives.
Novel antipsychotics have been in use
for three or four years in our country. Be-
cause of their high price, which can be
many times higher then the price of con-
ventional antipsychotics, Croatian health
insurance controls their prescription17.
By the decision of Croatian health insur-
ance risperdon and olanzapin are reser-
ved for schizophrenic patients that are
refracterous to therapy by conventional
antipsychotics or react to conventional
antipsychotics with very strong side ef-
fects, and klozapin is treated as a reserve
antipsychotic medication. Probably be-
cause of this decision, but also because of
widespread habit of prescribing conven-
tional antipsychotics, more than half of
schizophrenic patients in Croatia are still
on conventional antipsychotics13. Con-
ventional antipsychotics are practically
prescribed to all schizophrenic patients
who respond well on them, and have
fewer side effects18. Indirectly, it could be
inferred that »better« patients, i.e. pa-
tients with less severe illness, are pre-
scribed conventional antipsychotics more
often. Therefore, novel antipsychotics, al-
though they significantly improve the
quality of life, in spite of their efficiency
could not in such a group considerably
improve the quality of life, although they
did succeed in bringing satisfactory social
remission.
Moreover, patients using novel anti-
psychotics have been treated for shorter
time then patients using conventional an-
tipsychotics. In order to finish the study
in given time, we have insisted on social
remission for at least six months while
they were on their medicamentation, just
to obtain sufficient number of patients
taking novel antipsychotics. This leaves
the possibility open that long-term ther-
apy with novel antipsychotics could bring
the quality of life of schizophrenic pa-
tients to level higher than the one achie-
ved by conventional antipsychotics.
There is one other possibility, i.e. ex-
planation of eventual future proof that
novel antipsychotics do not have any sig-
nificant advantages in regard to improv-
ing the quality of life over conventional
antipsychotics. This is the fact that in re-
cent years more and more attention is
paid to the quality of life of the patients,
which has coincided with introduction of
novel antipsychotics19,20. Simply put, dur-
ing the previous time when the conven-
tional antipsychotics were introduced
more attention was paid to calming pa-
tients and removal of psychotic symp-
toms, whereas today more attention is
paid to quality of life.
To conclude, we can say that this stu-
dy has not confirmed the hypothesis that
novel antipsychotics have any advanta-
ges over conventional antipsychotics with
regard to the quality of life, apart from
social activity parameter. However, bear-
ing in mind that novel antipsychotics
were prescribed to patients who did not
primarily respond well to conventional
antipsychotics, and that the duration of
the therapy was relatively short, which
could indicate more severe form of illness,
and that the treatment was not suffi-
ciently long, obtained results will have to
be verified in future studies.
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ZNA^ENJE ATIPI^NIH ANTIPSIHOTIKA U KVALITETI @IVOTA
SHIZOFRENIH BOLESNIKA
S A @ E T A K
Kvaliteti `ivljenja shizofrenih bolesnika poklanja se sve ve}a pozornost. Rezultati
niza klini~kih studija ukazuju na ~injenicu da su novi, atipi~ni antipsihotici jednako ili
~ak u~inkovitiji od klasi~nih, no da imaju znatno manje nuspojava i da je kvaliteta
`ivljenja bolesnika koji uzimaju nove antipsihotike znatno bolja od kvalitete `ivljenja
bolesnika koji su na klasi~nim antipsihoticima. @ele}i na vlastitim pacijentima pro-
vjeriti ovu postavku, ispitali smo kvalitetu `ivljenja 80 shizofrenih bolesnica koje su
najmanje {est mjeseci, uzimaju}i redovito antipsihotike, bili pod redovitom psihijatrij-
skom ambulantnom kontrolom i u stanju socijale remisije. U ovom istra`ivanju, 40
bolesnica uzimala je klasi~ne, tipi~ne antipsihotike, dok ih je 40 bilo na novim, atipi-
~nim antipsihoticima. U istra`ivanju smo primijenili upitnik za kvalitetu `ivljenja pre-
ma »Heinrichs- Hanlon-Carpenter – Quality of life questionnaire«. Na|eno je da se
promatrane skupine glede kvalitete `ivljenja razlikuju samo u segmentu socijalne ak-
tivnosti. Ostavljaju}i otvoreno pitanje razlike utjecaja tipi~nih i atipi~nih antipsihotika
na kvalitetu `ivljenja shizofrenih bolesnika, autori tra`e mogu}e razloge dobivenih re-
zultata.
